Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence

Wang, Lisheng; Wang, Yiru; Ye, Dawei; Liu, Qingquan

doi:10.1016/j.ijantimicag.2020.105948

Cited by 977 publications

(945 citation statements)

References 65 publications

Supporting

Mentioning

815

Contrasting

Unclassified

Order By: Relevance

“…This drug also showed 1.13 M at half-maximal concentration against SARS-CoV-2 and blocked viral infection by increasing the endosomal pH required for viral fusion (Fig. 2) (30). Azithromycin has been suggested to act in combination with Chloroquine/hydroxychloroquine against SARs-CoV-2 (31).…”

Section: Chloroquine/hydroxychloroquine: Is It Promising For Covid-19?mentioning

confidence: 95%

“…The in vitro study findings revealed that remdesivir and chloroquine are highly effective in the control of COVID-19. Because these compounds have already passed the safety test against various diseases, they could be used to treat the patients suffering from COVID-19 infection (30). The patients affected with COVID-19 infection and who have no complications with the chloroquine drug are advised to take 500 mg of chloroquine two times a day for 10 days (31).…”

Section: Chloroquine/hydroxychloroquine: Is It Promising For Covid-19?mentioning

confidence: 99%

See 1 more Smart Citation

COVID-19: an update on diagnostic and therapeutic approaches

et al. 2020

View full text Add to dashboard Cite

The unexpected pandemic set off by the novel coronavirus 2019 (COVID-19) has caused severe panic among people worldwide. COVID-19 has created havoc, and scientists and physicians are urged to test the efficiency and safety of drugs used to treat this disease. In such a pandemic situation, various steps have been taken by the government to control and prevent the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). This pandemic situation has forced scientists to rework strategies to combat infectious diseases through drugs, treatment, and control measures. COVID-19 treatment requires both limiting viral multiplication and neutralizing tissue damage induced by an inappropriate immune reaction. Currently, various diagnostic kits to test for COVID-19 are available, and repurposing therapeutics for COVID-19 has shown to be clinically effective. As the global demand for diagnostics and therapeutics continues to rise, it is essential to rapidly develop various algorithms to successfully identify and contain the virus. This review discusses the updates on specimens/samples, recent efficient diagnostics, and therapeutic approaches to control the disease and repurposed drugs mainly focusing on chloroquine/hydroxychloroquine and convalescent plasma (CP). More research is required for further understanding of the influence of diagnostics and therapeutic approaches to develop vaccines and drugs for COVID-19.

show abstract

Section: Chloroquine/hydroxychloroquine: Is It Promising For Covid-19?mentioning

confidence: 95%

Section: Chloroquine/hydroxychloroquine: Is It Promising For Covid-19?mentioning

confidence: 99%

COVID-19: an update on diagnostic and therapeutic approaches

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Some people have no symptoms (mild pneumonia). The most common symptoms of COVID-19 according to a recent WHO report that was done on more than 70,000 cases in China are the following: fever (in 88% of cases), dry cough and sore throat (68%), fatigue (38%) and diarrhea (4%), which were similar to SARS-CoV and MERS-CoV [39,40]. Furthermore, severe shortness of breath occurred in nearly 20% of cases and around 13% had a sore throat or severe headache.…”

Section: Symptomsmentioning

confidence: 99%

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status

El-Aziz

Stockand

2020

Infection, Genetics and Evolution

309

300

View full text Add to dashboard Cite

show abstract

“…In December 2019, a new strain of coronavirus emerged in Wuhan city of Hubei province in China and has since spread globally. The virus belongs to clade B of family Coronaviridae in the order Nidovirales, and genera Betacoronavirus and caused pulmonary disease outbreak [1,2]. It is positive-sense RNA, enveloped and non-segmented virus and named as SARS-CoV-2 as it share 82% sequence identity with SARS coronavirus (SARS-CoV) [3,4].…”

Section: Introductionmentioning

confidence: 99%

Immuno-informatics Characterization SARS-CoV-2 Spike Glycoprotein for Prioritization of Epitope based Multivalent Peptide Vaccine

Ismail

Ahmad

Azam

2020

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic caused by SARS-CoV-2 is a public-health emergency of international concern and thus calling for the development of safe and effective therapeutics and prophylactics particularly a vaccine to protect against the infection. SARS-CoV-2 spike glycoprotein is an attractive candidate for vaccine, antibodies and inhibitor development because of many roles it plays in attachment, fusion and entry into the host cell. In this study, we characterized the SARS-CoV-2 spike glycoprotein by immune-informatics techniques to put forward potential B and T cell epitopes, followed by the use of epitopes in construction of a multi-epitope peptide vaccine construct (MEPVC). The MEPVC revealed robust host immune system simulation with high production of immunoglobulins, cytokines and interleukins. Stable conformation of the MEPVC with a representative innate immune TLR3 receptor was observed involving strong hydrophobic and hydrophilic chemical interactions, along with enhanced contribution from salt-bridges towards inter-molecular stability. Molecular dynamics simulation in solution aided further in interpreting strong affinity of the MEPVC for TLR3. This stability is the attribute of several vital residues from both TLR3 and MEPVC as shown by radial distribution function (RDF) and a novel analytical tool axial frequency distribution (AFD). Comprehensive binding free energies estimation was provided at the end that concluded major domination by electrostatic and minor from van der Waals. Summing all, the designed MEPVC has tremendous potential of providing protective immunity against COVID-19 and thus has the potential to be considered in experimental studies.

show abstract

Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence

Cited by 977 publications

References 65 publications

COVID-19: an update on diagnostic and therapeutic approaches

COVID-19: an update on diagnostic and therapeutic approaches

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status

Immuno-informatics Characterization SARS-CoV-2 Spike Glycoprotein for Prioritization of Epitope based Multivalent Peptide Vaccine

Contact Info

Product

Resources

About